ALX ONCOLOGY HOLDINGS INC APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ALX ONCOLOGY HOLDINGS INC (ALXO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.68 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.68M, a 25.61% increase year-over-year.
- ALX ONCOLOGY HOLDINGS INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.51M, a 51.90% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.52M, a 63.74% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.14M, a 70.55% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $12.58M, a 53.57% decline from fiscal 2024.
- ALX ONCOLOGY HOLDINGS INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $27.09M, a 3.12% increase from fiscal 2023.
- ALX ONCOLOGY HOLDINGS INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $26.27M, a 10.21% increase from fiscal 2022.
- ALX ONCOLOGY HOLDINGS INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $23.84M, a 71.33% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.68M 10-Q · filed 2026-08-06 | $5.19M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $2.51M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $12.58M 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $2.52M 10-Q · filed 2025-11-07 | $4.66M derived: sum of 2 quarters · filed 2026-08-06 | $9.87M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $2.14M 10-Q · filed 2026-08-06 | $7.35M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $5.22M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $27.09M 10-K · filed 2026-03-09 | |||
| 2024-09-30 | $6.95M 10-Q · filed 2025-11-07 | $14.20M derived: sum of 2 quarters · filed 2025-11-07 | $21.23M derived: sum of 3 quarters · filed 2025-11-07 | |
| 2024-06-30 | $7.25M 10-Q · filed 2025-11-07 | $14.28M derived: sum of 2 quarters · filed 2025-11-07 | ||
| 2024-03-31 | $7.03M 10-Q · filed 2025-11-07 | |||
| 2023-12-31 | $26.27M 10-K · filed 2026-03-09 | |||
| 2023-09-30 | $6.96M 10-Q · filed 2024-11-07 | $13.20M derived: sum of 2 quarters · filed 2024-11-07 | $19.55M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $6.24M 10-Q · filed 2024-11-07 | $12.59M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $6.35M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $23.84M 10-K · filed 2025-03-06 | |||
| 2022-09-30 | $6.21M 10-Q · filed 2023-11-13 | $12.04M derived: sum of 2 quarters · filed 2023-11-13 | $17.54M derived: sum of 3 quarters · filed 2023-11-13 | $23.23M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | $5.84M 10-Q · filed 2023-11-13 | $11.34M derived: sum of 2 quarters · filed 2023-11-13 | $17.02M derived: sum of 3 quarters · filed 2024-03-07 | $21.21M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | $5.50M 10-Q · filed 2023-11-13 | $11.19M derived: sum of 2 quarters · filed 2024-03-07 | $15.38M derived: sum of 3 quarters · filed 2024-03-07 | $17.61M derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | $5.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $9.88M derived: sum of 2 quarters · filed 2024-03-07 | $12.11M derived: sum of 3 quarters · filed 2024-03-07 | $13.91M 10-K · filed 2024-03-07 |
| 2021-09-30 | $4.19M 10-Q · filed 2022-11-08 | $6.43M derived: sum of 2 quarters · filed 2022-11-08 | $8.23M 10-Q · filed 2021-11-12 | $9.97M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-06-30 | $2.24M 10-Q · filed 2022-11-08 | $4.04M derived: sum of 2 quarters · filed 2022-11-08 | $5.78M derived: sum of 3 quarters · filed 2023-03-09 | $6.47M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-03-31 | $1.80M 10-Q · filed 2022-11-08 | $3.54M derived: sum of 2 quarters · filed 2023-03-09 | $4.23M derived: sum of 3 quarters · filed 2023-03-09 | $7.08M derived: sum of 4 quarters · filed 2023-03-09 |
| 2020-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $2.43M derived: sum of 2 quarters · filed 2023-03-09 | $5.29M derived: sum of 3 quarters · filed 2023-03-09 | $5.44M 10-K · filed 2023-03-09 |
| 2020-09-30 | $689.00K 10-Q · filed 2021-11-12 | $3.54M derived: sum of 2 quarters · filed 2021-11-12 | $3.69M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $2.85M 10-Q · filed 2021-08-12 | $3.00M derived: sum of 2 quarters · filed 2021-08-12 | ||
| 2020-03-31 | $151.00K 10-Q · filed 2021-08-12 | |||
| 2019-12-31 | $297.00K 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $86.00K 10-Q · filed 2020-11-12 | $146.00K derived: sum of 2 quarters · filed 2020-11-12 | $222.00K derived: sum of 3 quarters · filed 2020-11-12 | |
| 2019-06-30 | $60.00K 10-Q · filed 2020-11-12 | $136.00K derived: sum of 2 quarters · filed 2020-11-12 | ||
| 2019-03-31 | $76.00K 10-Q · filed 2020-11-12 | |||
| 2018-12-31 | $269.00K 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |